DK2121944T3 - In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser - Google Patents

In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser

Info

Publication number
DK2121944T3
DK2121944T3 DK08707977.8T DK08707977T DK2121944T3 DK 2121944 T3 DK2121944 T3 DK 2121944T3 DK 08707977 T DK08707977 T DK 08707977T DK 2121944 T3 DK2121944 T3 DK 2121944T3
Authority
DK
Denmark
Prior art keywords
qpct
treatment
alzheimer
disease
related disorders
Prior art date
Application number
DK08707977.8T
Other languages
Danish (da)
English (en)
Inventor
Stephan Schilling
Holger Cynis
Torsten Hoffmann
Hans-Ulrich Demuth
Michael Wermann
Katrin Schulz
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Application granted granted Critical
Publication of DK2121944T3 publication Critical patent/DK2121944T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
DK08707977.8T 2007-01-19 2008-01-18 In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser DK2121944T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88564907P 2007-01-19 2007-01-19
PCT/EP2008/050532 WO2008087197A1 (en) 2007-01-19 2008-01-18 In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders

Publications (1)

Publication Number Publication Date
DK2121944T3 true DK2121944T3 (da) 2011-10-31

Family

ID=39271322

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08707977.8T DK2121944T3 (da) 2007-01-19 2008-01-18 In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser

Country Status (13)

Country Link
US (1) US20080200567A1 (enExample)
EP (2) EP2121944B1 (enExample)
JP (1) JP2010516235A (enExample)
AT (1) ATE521711T1 (enExample)
AU (1) AU2008206936B2 (enExample)
CA (1) CA2675192A1 (enExample)
DK (1) DK2121944T3 (enExample)
ES (1) ES2372229T3 (enExample)
HR (1) HRP20110651T1 (enExample)
NZ (1) NZ578513A (enExample)
SI (1) SI2121944T1 (enExample)
WO (1) WO2008087197A1 (enExample)
ZA (1) ZA200904353B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9277737B2 (en) 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
JP5612860B2 (ja) * 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
US9656991B2 (en) * 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8772508B2 (en) * 2007-04-18 2014-07-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8227498B2 (en) * 2007-04-18 2012-07-24 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9034907B2 (en) * 2007-04-18 2015-05-19 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128986A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
WO2008128987A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Novel inhibitors
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
AU2008297070A1 (en) * 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
NZ586665A (en) * 2008-01-14 2011-12-22 Probiodrug Ag MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE (Qpct)
KR101682728B1 (ko) * 2008-07-31 2016-12-05 프로비오드룩 아게 신경변성 질환에 대한 진단적/예후적 지표로서 글루타미닐 사이클라제
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
WO2012022804A1 (en) 2010-08-19 2012-02-23 Probiodrug Ag Crystal structure of glutaminyl cyclase
WO2012028706A1 (en) 2010-09-02 2012-03-08 Probiodrug Ag IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
US8741614B2 (en) 2010-11-02 2014-06-03 Probiodrug Ag Crystal structure of isoglutaminyl cyclase
US20130052203A1 (en) 2011-08-12 2013-02-28 Probiodrug Ag In vivo screening models for treatment of qc-related disorders
EP2879719B1 (en) 2012-08-01 2018-07-04 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
WO2017079547A2 (en) * 2015-11-04 2017-05-11 The Scripps Research Institute Compositions and methods for treating cystic fibrosis
MC200185B1 (fr) 2016-09-16 2017-10-04 Coronal Audio Dispositif et procédé de captation et traitement d'un champ acoustique tridimensionnel
MC200186B1 (fr) 2016-09-30 2017-10-18 Coronal Encoding Procédé de conversion, d'encodage stéréophonique, de décodage et de transcodage d'un signal audio tridimensionnel

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
EP1961416B1 (en) * 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
ATE462432T1 (de) * 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
NZ543146A (en) 2003-05-05 2008-09-26 Probiodrug Ag Use of effectors of glutaminyl cyclase (QC) activity in combination with inhibitors of DP IV or DP IV-like enzymes for the treatment of conditions that can be treated by modulation of QC-and/or DPIV-activity
JP2007509898A (ja) * 2003-11-03 2007-04-19 プロビオドルグ エージー 神経障害治療に有用な組合せ
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
GB0704100D0 (en) 2006-03-17 2007-04-11 Vodafone Plc Improvements in an ehspa architecture
NZ575727A (en) * 2006-09-21 2011-12-22 Probiodrug Ag Novel genes related to glutaminyl cyclase

Also Published As

Publication number Publication date
EP2395095A1 (en) 2011-12-14
ZA200904353B (en) 2010-09-29
AU2008206936B2 (en) 2013-03-14
ATE521711T1 (de) 2011-09-15
AU2008206936A1 (en) 2008-07-24
CA2675192A1 (en) 2008-07-24
HRP20110651T1 (hr) 2011-10-31
JP2010516235A (ja) 2010-05-20
WO2008087197A1 (en) 2008-07-24
NZ578513A (en) 2012-01-12
US20080200567A1 (en) 2008-08-21
EP2121944B1 (en) 2011-08-24
EP2121944A1 (en) 2009-11-25
SI2121944T1 (sl) 2011-12-30
ES2372229T3 (es) 2012-01-17

Similar Documents

Publication Publication Date Title
DK2121944T3 (da) In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser
WO2009034158A3 (en) Transgenic mice
WO2008121199A3 (en) Transgenic animal models of disease
DK2336329T3 (da) Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer
PA8672101A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
CY2016029I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
NO20076563L (no) Anti- MCP-1 antistoffer, sammensetninger og anvendelser
DK3156414T3 (da) Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
ATE462787T1 (de) Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington
EP2007875A4 (en) CELLS DERMATED FROM DERMA FOR HISTOLOGICAL ENGINEERING APPLICATIONS
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
ATE554096T1 (de) Verfahren zum erhöhen der resistenz gegen sojabohnenrost in transgenen pflanzen
BR112013033348A2 (pt) meios e processos para a determinação de modelos de previsão associados com um fenótipo
EA200900210A1 (ru) Способ и набор для прогнозирования успеха имплантации при искусственном оплодотворении
WO2007111938A3 (en) Inflammation-inhibitory serum factors and uses thereof
Castillo-Mariqueo et al. Clasping, ledge-score coordination and early gait impairments as primary behavioural markers of functional impairment in Alzheimer's disease
Rezzani et al. Morphological and biochemical studies on aging and autophagy
DK1785039T3 (da) Pelleter af planteprotein
ATE511348T1 (de) Transgenes modell für morbus alzheimer
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
EP2415868A4 (en) METHOD AND KIT FOR EVALUATING OBESITY DEVELOPMENT PREDISPOSITION, ANTI-OBESITY AGENT AND SCREENING METHOD, NON-HUMAN ANIMAL, ADIPOSE TISSUE, ADIPOCYTE, PROCESS FOR PRODUCTION OF TRANSGENIC MOUSE, ANTIGEN, AND 'ANTIBODY
WO2013024043A3 (en) In vivo screening models for treatment of qc-related disorders
WO2004062627A3 (en) In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders
WO2007135570A8 (en) Pink1 deficient animals, screening methods, and related therapeutics
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen